<|ref|>image<|/ref|><|det|>[[116, 95, 912, 323]]<|/det|>


<|ref|>image<|/ref|><|det|>[[115, 323, 912, 551]]<|/det|>


<|ref|>image<|/ref|><|det|>[[115, 560, 912, 790]]<|/det|>


<|ref|>figure_title<|/ref|><|det|>[[64, 798, 943, 822]]<|/det|>
Fig. 3. Image-derived biodistribution in NHPs (SUV): a Tracer only NHP. b Carrier-added 1 mg/kg nivolumab NHP. c Carrier-added 3 mg/kg nivolumab NHP. The spleen uptake in tracer only NHP is higher than the uptake in carrier-added NHPs.

<|ref|>figure_title<|/ref|><|det|>[[66, 832, 110, 843]]<|/det|>
Table 2

<|ref|>figure_title<|/ref|><|det|>[[66, 843, 592, 856]]<|/det|>
SUV and Changes In Splenic Uptake of  \( {}^{89} \) Zr-Nivolumab in tracer only vs. Carrier-Added Studies in NHPs.

<|ref|>table<|/ref|><|det|>[[67, 858, 940, 935]]<|/det|>
<table><tr><td></td><td>Tracer only</td><td>Carrier-Added 1 mg/kg</td><td></td><td>Carrier-Added 3 mg/kg</td><td></td></tr><tr><td>Time after infusion</td><td>SUV</td><td>SUV</td><td>% change \( ^{a} \)</td><td>SUV</td><td>% change \( ^{a} \)</td></tr><tr><td>24 h (1 day)</td><td>11.47</td><td>2.69</td><td>−75.5%</td><td>2.81</td><td>−75.2%</td></tr><tr><td>96 h (4 days)</td><td>16.77</td><td>3.12</td><td>−83.8%</td><td>2.84</td><td>−84.4%</td></tr><tr><td>144 h (6 days)</td><td>16.44</td><td>2.55</td><td>−83.2%</td><td>2.81</td><td>−84.6%</td></tr><tr><td>192 h (8 days)</td><td>17.63</td><td>2.50</td><td>−86.3%</td><td>2.62</td><td>−87.0%</td></tr></table>

<|ref|>text<|/ref|><|det|>[[76, 939, 362, 952]]<|/det|>
 \( ^{a} \)  Percentages calculated from SUV of tracer only NHP.